Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011
Wed, February 23, 2011
Tue, February 22, 2011

Somaxon Pharmaceuticals to Present at Upcoming Investor Conferences

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. to-present-at-upcoming-investor-conferences.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

SAN DIEGO--([ BUSINESS WIRE ])--Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxona™s president and chief executive officer, is scheduled to present at the following investor conferences:

  • Monday, March 7, 2011
    Cowen and Company 31st Annual Health Care Conference
    The Boston Marriott Copley Place a" Boston, MA
    4:00 p.m. ET (1:00 p.m. PT)
  • Monday, March 14, 2011
    Roth 23rd Annual OC Growth Stock Conference
    The Ritz Carlton a" Laguna Niguel, CA
    12:30 p.m. ET (9:30 a.m. PT)
  • Wednesday, March 16, 2011
    Barclays Capital 2011 Global Healthcare Conference
    Loews Miami Beach Hotel a" Miami, FL
    3:45 p.m. ET (12:45 p.m. PT)

A live webcast of each presentation will be available in the Investor Relations section of the companya™s Web site under Event Scheduler at [ www.somaxon.com ]. Each webcast will be accessible following conclusion of the live event and archived for approximately 90 days.

To be added to Somaxon Pharmaceuticalsa™ email list, please visit [ http://bit.ly/Somaxon-email-list ].

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and of late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxona™s product Silenor®, now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the companya™s web site at [ www.somaxon.com ].